Source: www.reuters.com
1 Min Read
COPENHAGEN (Reuters) - Danish drug developer Novo Nordisk posted on Wednesday fourth quarter operating profit that was below expectations, and said it expected to generate sales growth in local currencies of between 6% and 10% in 2022.
Novo reported operating profit of 13.63 billion, an increase of 16% over the corresponding period last year, but below an average of 14.36 billion forecast by analysts in a Refinitiv poll.
Novo also said it expected operating profit growth in local currencies in 2022 of 4% to 8%.
Reporting by Nikolaj Skydsgaard; Editing by Clarence Fernandez
